Comparison
Teriparatid vs. Triptorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
52232-67-4
57773-63-4
Molecular weight
4117.8 g/mol
1311.45 g/mol
Half-life
1 h
3 h
Sequence
Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-PhepGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Mechanism of action
Teriparatid
Teriparatide corresponds to the biologically active first 34 amino acids of human parathyroid hormone and binds the PTH-1 receptor on bone and kidney cells. The literature describes that intermittent receptor activation preferentially stimulates the activity of bone-forming osteoblasts, whereas continuously elevated PTH exposure (as in hyperparathyroidism) tends to favor bone resorption. This time-dependent difference is regarded as the mechanistic basis for the bone-anabolic effect observed in studies.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
4
of which in humans
4
4
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
2
3
Legal status
Full entries
Frequently asked questions
- What is the difference between Teriparatid and Triptorelin?
- Teriparatid is classified as "Research other", while Triptorelin is classified as "Research other". Teriparatid: Teriparatide is the recombinant N-terminal fragment 1-34 of human parathyroid hormone (PTH). It is regulatory-approved and studied in the scientific literature as a bone-anabolic agent for the treatment of osteoporosis. Unlike antiresorptive agents, studies attribute to it an effect that stimulates new bone formation. Triptorelin: Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Teriparatid or Triptorelin?
- The highest available evidence level is "Human RCT" for Teriparatid and "Human RCT" for Triptorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Teriparatid and Triptorelin in Germany and the United States?
- Germany: Teriparatid — Prescription, Triptorelin — Prescription. United States: Teriparatid — Prescription, Triptorelin — Prescription. These are factual summaries with source and review date on the individual pages.